Publications by authors named "H G Prakash"
Background: Diabetes is a chronic medical condition with severe complications, mainly caused by unhealthy lifestyles in genetically susceptible individuals. There has been a growing interest in the role of mobile health technologies in achieving better self-efficacy in managing diabetes. This study attempts to assess the impact of a web-based model on improving the diabetes status among Type 2 diabetic patients attending a tertiary care hospital in southern India.
View Article and Find Full Text PDFArticle Synopsis
- Mesenchymal stem cells (MSCs) have shown promise for treating diseases with immune disorders, such as Graft-versus-Host-Disease (GVHD), and their effectiveness depends on how they behave after administration.
- The study involved deriving human MSCs from bone marrow and Wharton's Jelly, preconditioning them in low-oxygen environments, and assessing their impact on immune responses, particularly looking at T cell behavior and macrophage polarization.
- Results indicated that MSCs preconditioned through hypoxia and apoptosis (especially those from Wharton's Jelly) had superior immune-modulating abilities, improving Treg differentiation and shifting macrophages toward a more anti-inflammatory state, suggesting a novel approach for treating aGVHD.
Developing pure diastereoisomeric molecular hybrids for the selective inhibition of bacterial growth opened new avenues for combating the ever-increasing microbial resistance. Considering this, a series of diastereoisomeric pure pyrazolyl-dihydrofurans (7a-7y) were synthesized and characterized using NMR, LCMS, and X-ray crystallography. DFT based method was used to explore the configurational stability of cis over trans isomeric form.
View Article and Find Full Text PDFLung cancer is a severe challenge to the health care system with intrinsic resistance to first and second-line chemo/radiotherapies. In view of the sterile environment of lung cancer, several immunotherapeutic drugs including nivolumab, pembrolizumab, atezolizumab, and durvalumab are currently being used in clinics globally with the intention of releasing exhausted T-cells back against refractory tumor cells. Immunotherapies have a limited response rate and may cause immune-related adverse events (irAEs) in some patients.
View Article and Find Full Text PDFObjectives: Aim of this study was to explore the immune-related lncRNAs having prognostic role and establishing risk score model for better prognosis and immunotherapeutic coherence for esophageal cancer (EC) patients.
Methods: To determine the role of immune-related lncRNAs in EC, we analyzed the RNA-seq expression data of 162 EC patients and 11 non-cancerous individuals and their clinically relevant information from the cancer genome atlas (TCGA) database. Bioinformatic and statistical analysis such as Differential expression analysis, co-expression analysis, Kaplan Meier survival analysis, Cox proportional hazards model, ROC analysis of risk model was employed.